You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Baxter
Medtronic
McKesson
Merck

Last Updated: April 16, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022474

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

NDA 022474 describes ELLA, which is a drug marketed by Lab Hra Pharma and is included in one NDA. It is available from three suppliers. There are eight patents protecting this drug and one Paragraph IV challenge. Additional details are available on the ELLA profile page.

The generic ingredient in ELLA is ulipristal acetate. There are six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the ulipristal acetate profile page.
Summary for 022474
Tradename:ELLA
Applicant:Lab Hra Pharma
Ingredient:ulipristal acetate
Patents:8
Pharmacology for NDA: 022474
Suppliers and Packaging for NDA: 022474
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ELLA ulipristal acetate TABLET;ORAL 022474 NDA A-S Medication Solutions 50090-2835 50090-2835-0 1 BLISTER PACK in 1 CARTON (50090-2835-0) > 1 TABLET in 1 BLISTER PACK
ELLA ulipristal acetate TABLET;ORAL 022474 NDA A-S Medication Solutions 50090-5422 50090-5422-0 1 BLISTER PACK in 1 CARTON (50090-5422-0) > 1 TABLET in 1 BLISTER PACK
Paragraph IV (Patent) Challenges for 022474
Tradename Dosage Ingredient NDA Submissiondate
ELLA TABLET;ORAL ulipristal acetate 022474 2014-08-13

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength30MG
Approval Date:Aug 13, 2010TE:ABRLD:Yes
Patent:  Start TrialPatent Expiration:Apr 13, 2030Product Flag?Substance Flag?Delist Request?
Patented Use:A METHOD FOR CONTRACEPTION COMPRISING THE STEP OF ORAL ADMINISTRATION A DOSAGE OF 20 MG TO 30 MG OF ULIPRISTAL ACETATE TO A WOMAN WITHIN 72 HOURS AND UP TO 120 HOURS AFTER AN UNPROTECTED INTERCOURSE
Patent:  Start TrialPatent Expiration:Apr 13, 2030Product Flag?Substance Flag?Delist Request?
Patented Use:A METHOD FOR CONTRACEPTION, THE METHOD COMPRISING ADMINISTERING A TABLET COMPRISING 20 MG TO 30 MG OF ULIPRISTAL ACETATE TO A WOMAN WITHIN 120 HOURS AFTER AN UNPROTECTED INTERCOURSE
Patent:  Start TrialPatent Expiration:Jun 12, 2030Product Flag?Substance Flag?Delist Request?
Patented Use:ELLA IS A PROGESTERONE AGONIST/ANTAGONIST EMERGENCY CONTRACEPTION INDICATED FOR THE PREVENTION OF PREGNANCY FOLLOWING UNPROTECTED INTERCOURSE OR A KNOWN OR SUSPECTED CONTRACEPTIVE FAILURE. ELLA CAN BE TAKEN WITH OR WITHOUT FOOD

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Baxter
AstraZeneca
McKinsey
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.